JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic...
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and...
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is...
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral...
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule...
‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒...
‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3...
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is...